4-minute read
Innovative drugs need a new regulatory approach
Access to new drugs in Canada.
IEDM – Pourquoi faut-il attendre pour avoir accès à de nouveaux médicaments? – Mathieu Bédard
April 5, 2018 | 26 min. 07 sec. | Isabelle (98.5 FM) Interview (in French) with Mathieu Bédard, Economist at the MEI, […]
IEDM – Nouveaux médicaments : les malades attendent 15 mois de trop – Mathieu Bédard
April 5, 2018 | 14 min. 36 sec. | Québec aujourd’hui (BLVD 102.1 FM) Interview (in French) with Mathieu Bédard, Economist at […]
5-minute read
Protéger la vie privée, mais aussi la liberté de décider pour soi-même
The protection of private data on the Internet.
5-minute read
Nouveaux médicaments : la longue marche réglementaire
Access to new drugs in Canada.
8-minute read
Innovative Drugs: A Bureaucratic Obstacle Course
Innovative drugs help people enjoy longer, healthier, more productive lives. They also allow our health care systems to save money. However, the reimbursement of new drugs by Canada’s public plans can face considerable delays due to a very burdensome regulatory process. Far from resolving this problem, a new reform will duplicate certain stages of this process and possibly lengthen it.
4-minute read
The CRTC’s great wireless non-decision
The CRTC and wireless competition.
3-minute read
Free my grapes: Dismantling Canada’s interprovincial barriers to trade
There are many good reasons to bring down provincial trade barriers.
4-minute read
Slashing Med School Admissions Isn’t How You Deal With A Doctor Shortage
Government control over access to medical training hurts patients.
4-minute read
Looming Trade War Isn’t The Only Problem For Canada’s Economy
The probability of a trade war is high.